Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02325557 · ClinicalTrials.gov registry record · Phase 1

ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Phase 1 study of Prostate Cancer and Cancer, sponsored by Advaxis.

Completed
Registry status
Phase 1
Development phase
50
Enrollment target
8
Study locations

NCT02325557: Completed Phase 1 study of Prostate Cancer and Cancer, sponsored by Advaxis.

NCT02325557 is a Phase 1 study of Prostate Cancer and Cancer that has completed, run by Advaxis. The registered enrollment target is 50 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02325557, a Phase 1 study of Prostate Cancer and Cancer, has completed, sponsored by Advaxis.

COMPLETED
Registry status
Phase 1
Development phase
50 participants
Enrollment target
8
Study locations

Study Summary

A Phase 1/2 multicenter, dose determining, open-label study of ADXS31-142 monotherapy and a combination of ADXS31-142 and pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer. Part A will be dose-determining part of ADXS31-142 monotherapy. Part B will be dose-determining part of ADXS31-142 and pembrolizumab (MK-3475) in combination. Part B expansion will treat additional participants with the recommended dose from Part B.

Conditions Studied

Prostate Cancer Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG ADXS31-142

Study Locations (8)

Maryland

  • Recruiting - Rockville
  • Recruiting - Towson

Pennsylvania

  • Recrutiing - Philadelphia
  • Site - Philadelphia

California

  • Recruiting - San Francisco

Colorado

  • University of Colorado Health Sciences Center (UCHSC) - Aurora

New Jersey

  • - New Brunswick

Rhode Island

  • Recruiting - Providence

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2015-06-04
Est. Completion 2020-01-22
Phase Phase 1

Sponsor

Advaxis

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02325557

The ClinicalTrials.gov registry entry for NCT02325557 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Advaxis, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT02325557 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Maryland, Pennsylvania, California.

Frequently Asked Questions

What is clinical trial NCT02325557 about?

NCT02325557 is a clinical study titled "ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)". A Phase 1/2 multicenter, dose determining, open-label study of ADXS31-142 monotherapy and a combination of ADXS31-142 and pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer. Part A will be dose-determining part of ADXS31-142 monotherapy. Part B will be dose-...

What is the current status of trial NCT02325557?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2015-06-04. Estimated completion is 2020-01-22.

What conditions does trial NCT02325557 study?

This clinical trial studies the following conditions: Prostate Cancer, Cancer.

What interventions are being tested in trial NCT02325557?

The interventions under investigation include: Pembrolizumab (DRUG), ADXS31-142 (DRUG).

Who is sponsoring clinical trial NCT02325557?

This trial is sponsored by Advaxis, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02325557 being conducted?

This trial has 8 study locations across California, Colorado, Maryland, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.